This proposal is for a five-year renewal of our current NCI support: T32CA09510 (Surgical Oncology Research Training Program). The main aim of the Surgical Oncology Research Program at Memorial Sloan Kettering Cancer Center (MSKCC) is to strengthen academic surgical oncology research and to stimulate interest in basic research related to oncology. To achieve our objective the proposed Program with its large applicant pool designed to attract and develop the most promising and committed Surgical Oncologists in the country. Research opportunities are available in several laboratories within the Department of Surgery as well as laboratories at SKI related to immunology, immunopathology, genetics, and molecular biology. Additional training is available in Medical and Radiation Oncology and Biostatistics. Our records over the past 15 years show that we have been successful in attracting high quality surgeons early in their training who have gone on to make significant contributions in basic and clinical research related to oncology. The impressive publication record of these candidates and the academic positions that they hold upon leaving the Program records this. Our proposed Training Program is clearly based on our record and demonstrated need to develop young surgeons in Surgical Oncology training.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009501-20
Application #
7104340
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1984-09-01
Project End
2007-07-31
Budget Start
2006-07-01
Budget End
2007-07-31
Support Year
20
Fiscal Year
2006
Total Cost
$199,733
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Zhang, Jennifer Q; Zeng, Shan; Vitiello, Gerardo A et al. (2018) Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 6:434-447
Brandt, Whitney S; Bouabdallah, Ilies; Tan, Kay See et al. (2018) Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. J Thorac Cardiovasc Surg 155:1212-1224.e3
Brandt, Whitney S; Yan, Wanpu; Leeman, Jonathan E et al. (2018) Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. Ann Thorac Surg 106:848-855
Vitiello, Gerardo A; Medina, Benjamin D; Zeng, Shan et al. (2018) Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Clin Cancer Res 24:972-984
Lee, Jun H; Chang, Kevin K; Yoon, Changhwan et al. (2018) Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg 267:105-113
García Nores, Gabriela D; Ly, Catherine L; Savetsky, Ira L et al. (2018) Regulatory T Cells Mediate Local Immunosuppression in Lymphedema. J Invest Dermatol 138:325-335
Ly, Catherine L; Cuzzone, Daniel A; Kataru, Raghu P et al. (2018) Small numbers of CD4+ T cells can induce development of lymphedema. Plast Reconstr Surg :
García Nores, Gabriela D; Ly, Catherine L; Cuzzone, Daniel A et al. (2018) CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9:1970
Brandt, Whitney S; Yan, Wanpu; Zhou, Jian et al. (2018) Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. J Thorac Cardiovasc Surg :
Gardenier, Jason C; Kataru, Raghu P; Hespe, Geoffrey E et al. (2017) Topical tacrolimus for the treatment of secondary lymphedema. Nat Commun 8:14345

Showing the most recent 10 out of 166 publications